| Objective：Ulcerative colitis(UC) is a kind of inflammatory bowel disease. As the humanliving environment, diet habits, as well as the social environment change greatly, itsincidence is in the increasingly rising trend in recent years. Modern psychiatry makes UCas psychosomatic disease, different levels of anxiety depression symptoms exist in mostpatients[1].Paroxetine hydrochloride (Brand name:Seroxat）which were produced byTianjin schick pharmaceutical co. of China and the United States is the best for5-hydroxytryptamine(5-HT) reuptake inhibition, strongest potent broad-spectrumtreatment of anxiety and depression. Paroxetine hydrochloride were studied in thisexperiment in a state of UC patients with anxiety depression treatment of clinical curativeeffect and security, so as to provide theoretical basis for the treatment of UC.Methods：62cases were diagnosed and conforms to the standard into the group ofpatients according to the different treatment were randomly divided into two groups.Control group: to give the beauty salad lamictal tablet1.0g,3times/day of oral or beautysalad oxazine suppository0.5g,3times/day or the salad oxazine irrigation using amixed suspension (60g),1time/day. Experimental group: on the basis of the controlgroup at the same time give one paroxetine hydrochloride tablet each time20mg,1 time/day after breakfast for30min. Test before and after testing three hematuria dungroutine, liver function, renal function, electrolyte, etc. and relying on the electronicstomach and intestines, ultrasound to eliminate organic disease. It was scored usingdisease activity index (DAI), Hamilton anxiety scale (HAMA) and Hamilton depressionscale (HAMD) at0,1,4,8weeks. It was recorded using the Baron endoscopic grading,inflammatory bowel disease quality of life questionnaire (IBDQ) and Pittsburgh sleepquality index (PSQI) score at0,8weeks. During the trial all kinds of adverse reactions inpatients were detail recorded. All indicators were analyzed with statistical software SPSSl7.0, there were significant differences with P <0.05.Results：1. In the test group, treatment before DAI score7.39±1.85were significantly higherthan those after treatment of2.61±1.32;treatment before HAMA score19.96±3.26were significantly higher than those after treatment of4.18±1.44;treatment beforeHAMD score23.54±4.57were significantly higher than those after treatment of4.18±1.36;treatment before IBDQ score113.39±16.22were significantly lower than thoseafter treatment of157.75±18.72;treatment before PSQI score13.32±2.26weresignificantly higher than those after treatment of5.32±1.66.Experimental group beforeand after treatment of DAI, HAMA, HAMD, IBDQ and PSQI score differences werestatistically significant (P<0.05).2. In the control group, treatment before DAI score7.03±1.55were significantlyhigher than those after treatment of4.38±2.16;treatment before HAMA score18.97±2.68were significantly higher than those after treatment of10.65±2.30;treatment beforeHAMD score22.18±3.95were significantly higher than those after treatment of10.88±1.74;treatment before IBDQ score109.06±12.12were significantly lower after treatment of134.85±14.88; treatment before PSQI score14.09±2.11were significantlybetter than after treatment of7.15±1.28.The control group before and after treatment ofDAI, HAMA,HAMD, IBDQ and PSQI score differences were statistically significant (P<0.05).3. After8weeks treatment, the test group DAI score2.61±1.32had a significantlylower than the control group of4.38±2.16;Experimental group HAMAscore4.18±1.44were significantly lower than the control group of10.65±2.30;Experimental groupHAMD score4.18±1.36were significantly lower than the control group of10.88±1.74;Experimental group IBDQ score157.75±18.72were significantly higher than thecontrol group of134.85±14.88;Experimental group PSQI score5.32±1.66weresignificantly lower than the control group of7.15±1.28.Between the two groups inpatients with DAI, HAMA,HAMD, IBDQ and PSQI score differences were statisticallysignificant after treatment(P <0.05).4. After8weeks treatment, the treatment group and the control group in clinicalcurative effect of DAI, according to the integral situation decision.in the treatment group15cases were markedly effective,11cases were effective,2cases were ineffective, thetotal effective rate was92.9%;And in the control group8cases were markedly effective,16cases were effective and10cases were invalid, the total effective rate was70.6%;theexperimental group and control group after treatment Baron endoscope clinical curativeeffect, according to the classification situation decision13cases had been marked effect,12cases were effective and3cases were ineffective, the total effective rate was89.3%;And in the control group9cases had been marked effect, effectively and13cases,3had no effect, the total effective rate was64.7%.Visible experimental overall clinicalcurative effect is significantly higher than the control group, the difference was statistically significant (P <0.05).5. Basic clinical indexes before and after the treatment: the two groups before andafter the treatment were not significant changes in the three major routine,electrocardiogram, and liver and kidney function, etc. There was no significantdifference.Conclusion：Treated with paroxetine hydrochloride with anxiety depression disorders inpatients with ulcerative colitis, to improve the digestive tract symptoms and mooddisorders has significant curative effect and high safety.1.Conventional treatment of UC can alleviate intestinal symptoms, combined withparoxetine hydrochloride tablets in UC with anxiety depression, the effect is moreevident (to improve the clinical symptoms, reduce the HAMA and HAMD, IBDQ,improve the PSQI).2.The indicators in the table of DAI, Baron endoscopic stage, HAMA and HAMDare the exact index for observing with anxiety and depression in patients with UC.3. With the spirit of mood disorders in patients with UC, paroxetine hydrochloridehas curative effect, high safety and less adverse reaction, good tolerance, it is worthfurther for clinical application. |
PDF Full Text Request